EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ORGANOIDSCIENCES (476040) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of ORGANOIDSCIENCES KRW 1,130, price KRW 7,060, upside -84.0%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

O Thin data Sep 24, 2026

ORGANOIDSCIENCES

476040 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,130 KRW · Strongly overvalued (−84.0%)
!Quality 39/100
!Expensive Growth (revenue 3y +76.4 %/yr)
!Low debt · negative free cash flow
!Trails peers (1/7)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch ORGANOIDSCIENCES for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

48,150 KRW 6,200 KRW Fair Value 1,130 KRW May 2025 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

17‑month range 6,200 KRW – 48,150 KRW · fair‑value band 745.81 KRW – 1,413 KRW · the 7,060 KRW price screens above the 1,130 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow ORGANOIDSCIENCES in your weekly email

Every Wednesday you see whether ORGANOIDSCIENCES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Organoidsciences Ltd. develops regenerative therapies in South Korea.

Show more

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

Stock analysis

ORGANOIDSCIENCES (476040) currently trades at 7,060 KRW, while our model-based Fair Value estimate is 1,130 KRW, 84.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 745.81 KRW (bear) to 1,413 KRW (bull), the price of 7,060 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

ORGANOIDSCIENCES reported revenue of 2.4B KRW in FY2025 versus 270M KRW in FY2021, a compound +72.7%/yr. Reported net income was −15.4B KRW in FY2025.

Key figures

Market cap 46.3B KRW (≈ $34.5M) · P/S ratio 21.1 · Return on equity −93.1% · Return on assets (EBIT) −32.0% · Operating margin −2,955% · Revenue (TTM) 2.3B KRW · Revenue growth (YoY) −43.6% · Free cash flow −16.0B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 84% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −84%, 476040 screens richer than that median.

Fair Value models

Bear 745.81 KRW Fair Value 1,130 KRW Bull 1,413 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,872 KRW 2,509 KRW 3,745 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,872 KRW 2,509 KRW 3,745 KRW 54

Open the full fair value analysis →

Notify me when 476040 reaches fair value

Put 476040 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 39/100

Of which business quality 39 · Market factors (momentum, volatility) 3

Profitability 2
Margins and returns on capital today
Quality Growth 65
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 5
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 77
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+23.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,743.7% (2021) → −673.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

476040 screens overvalued: fair value 84% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ORGANOIDSCIENCES with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −84.0% · Bottom 25%
Profitability
Return on assets −32.1% · Bottom 25%
Growth and dividend
Revenue growth −43.6% · Bottom 25%
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.02× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ORGANOIDSCIENCES · Fair Value
1,130 KRW −84%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ORGANOIDSCIENCES Fair Value". https://www.fairvalue-calculator.com/stock/476040

Frequently asked questions

Is ORGANOIDSCIENCES (476040) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,130 KRW versus a price of 7,060 KRW, about −84% upside (overvalued).
What is the fair value of 476040?
Our model-based fair value for ORGANOIDSCIENCES is 1,130 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 7,060 KRW.
What is the quality score of 476040?
ORGANOIDSCIENCES has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ORGANOIDSCIENCES (476040)?
Our model-based price target is the fair value of 1,130 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 745.81 KRW, optimistic scenario 1,413 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ORGANOIDSCIENCES stock forecast for 2026?
Our models put fair value at 1,130 KRW, about −84% upside versus a price of 7,060 KRW (overvalued). Cautious scenario 745.81 KRW, optimistic scenario 1,413 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ORGANOIDSCIENCES (476040)?
ORGANOIDSCIENCES reported trailing-twelve-month revenue of about 2.3B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ORGANOIDSCIENCES (476040)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ORGANOIDSCIENCES it is 1,130 KRW per share (as of Sep 24, 2026), against a price of 7,060 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ORGANOIDSCIENCES stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 476040 trades above its calculated fair value: price 7,060 KRW, fair value 1,130 KRW, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 476040?
No. The price is what the market pays today (7,060 KRW); the fair value is what the company's own numbers justify (1,130 KRW). For ORGANOIDSCIENCES the two are 5,930 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ORGANOIDSCIENCES worth?
The market values ORGANOIDSCIENCES at about 46.3B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 7,060 KRW; our models calculate a fair value of 1,130 KRW per share.
What do the bullish and bearish scenarios say about 476040?
Our models span a range for ORGANOIDSCIENCES: cautious scenario 745.81 KRW, base 1,130 KRW, optimistic 1,413 KRW per share (as of Sep 24, 2026, price 7,060 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ORGANOIDSCIENCES (476040)?
Balance-sheet figures for ORGANOIDSCIENCES (as of Sep 24, 2026): return on equity −93.1%, debt of 0.09 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 476040 from its 52-week high?
ORGANOIDSCIENCES trades at 7,060 KRW, about 84% below its 52-week high of 44,600 KRW and 14% above the low of 6,200 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 1,130 KRW is for.
Which stocks are comparable to ORGANOIDSCIENCES?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ORGANOIDSCIENCES stock attractive at the current price?
The data as of Sep 24, 2026: price 7,060 KRW, calculated fair value 1,130 KRW (−84%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 476040 calculated?
We run ORGANOIDSCIENCES through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,130 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ORGANOIDSCIENCES itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ORGANOIDSCIENCES (476040)?
The closing price on Oct 2, 2026 was 7,060 KRW. Our model-based fair value is 1,130 KRW, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ORGANOIDSCIENCES right now?
The price sits above even our optimistic bull case (1,413 KRW). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (745.81 KRW to 1,413 KRW) leaves room in how you read the outcome.

Key figures of ORGANOIDSCIENCES

How large is the market capitalisation of ORGANOIDSCIENCES (476040)?
The market capitalisation of ORGANOIDSCIENCES is 46.3B KRW (≈ $34.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ORGANOIDSCIENCES (476040)?
The price-to-sales ratio of ORGANOIDSCIENCES is 21.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of ORGANOIDSCIENCES (476040)?
The return on equity (ROE) of ORGANOIDSCIENCES is −93.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ORGANOIDSCIENCES (476040)?
On an EBIT basis the return on assets of ORGANOIDSCIENCES is −32.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ORGANOIDSCIENCES (476040)?
The operating margin of ORGANOIDSCIENCES is −2,955% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ORGANOIDSCIENCES (476040)?
Revenue at ORGANOIDSCIENCES is growing −43.6% versus a year earlier (3y avg +76.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ORGANOIDSCIENCES (476040) generate?
The free cash flow of ORGANOIDSCIENCES is −16.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ORGANOIDSCIENCES (476040) carry?
The net debt of ORGANOIDSCIENCES is 295M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ORGANOIDSCIENCES in the live analysis

One click puts ORGANOIDSCIENCES on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.